Skip to main content
AmigoFish

STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month

From BiotechTV - News · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline.

Back to BiotechTV - News · Report a problem